Meeting Minutes

Date: Wednesday, May 15, 2019
Time: 10:00 AM – 12:00 PM
Location: Health Sciences Building, Room E202

Members Present:
1. H.D. “Toby” Bradshaw, Biology (Plant Expert)
2. Richard Grant, Washington National Primate Research Center
3. Garry Hamilton (Community Member)
4. Kevin Hybiske, Allergy and Infectious Diseases
5. David Koelle, Allergy and Infectious Diseases
6. Stephen Libby, Laboratory Medicine (IBC Chair)
7. Scott Meschke, Environmental & Occupational Health Sciences
8. Eric Stefansson, Environmental Health & Safety (Biosafety Officer, Animal Containment Expert)
9. Paul Swenson, Seattle-King Co. Dept. of Public Health (Community Member)

Commonly Used Abbreviations
IBC: Institutional Biosafety Committee
BSO: Biological Safety Officer
BUA: Biological Use Authorization
BSL: biosafety level
PI: Principal Investigator
IACUC: Institutional Animal Care and Use Committee
NIH: National Institutes of Health
DURC: Dual Use Research of Concern
SOP: standard operating procedure
1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:00 a.m. A quorum was present. Public members were introduced.

2. **REMEMBER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.

3. **APPROVAL OF MINUTES:**
   - The IBC Chair sought a motion to approve the minutes from the April 17, 2019 meeting.
   - A member made a motion to approve the April 17, 2019 minutes. Another member seconded the motion.
   - The committee voted unanimously to approve the April 17, 2019 meeting minutes. One member abstained.

4. **OLD BUSINESS:**
   - At the July 2018 meeting, Dr. Patel’s BUA was approved pending a lab inspection. This is still pending.
   - At the October 2018 meeting, Dr. Stuber’s BUA was approved pending a lab inspection and room changes to the BUA letter. This is still pending.
   - At the November 2018 meeting, Dr. Bornfeldt’s BUA was approved pending additions to the BUA letter. This is still pending.
   - At the February 2019 meeting, Dr. Liao’s BUA was approved pending a lab inspection and changes to the BUA. This has been completed, and the BUA letter has been sent out.
   - At the February 2019 meeting, Dr. Nahmani’s BUA was approved pending a lab inspection and verification of third generation lentiviral vectors. This is still pending.
   - At the March 2019 meeting, Dr. Bajjalieh’s BUA was approved pending additional information to the BUA. This is still pending.
   - At the March 2019 meeting, Dr. Hladik’s BUA was approved pending changes to the BUA application and a successful lab inspection. This has been completed, and the BUA letter has been sent out.
   - At the March 2019 meeting, Dr. Moreno’s BUA was approved pending a successful lab inspection and training completion. This is still pending.
   - At the April 2019 meeting, Dr. Giachelli’s BUA was approved pending a successful lab inspection. This has been completed, and the BUA letter has been sent out.
   - At the April 2019 meeting, Dr. Gottlieb’s BUA was approved pending an addition to the BUA letter. This is still pending.
   - At the April 2019 meeting, Dr. Jiao’s BUA was approved pending a successful lab inspection. This has been completed, and the BUA letter has been sent out.
   - At the April 2019 meeting, Dr. Kwon’s BUA was approved pending a successful lab inspection. This has been completed, and the BUA letter has been sent out.
   - At the April 2019 meeting, Dr. Smith’s BUA was approved pending a successful lab inspection. This has been completed, and the BUA letter has been sent out.
   - At the April 2019 meeting, Dr. Sweet’s BUA was approved pending a successful lab inspection. This has been completed, and the BUA letter has been sent out.
5. **BIOSAFETY OFFICER (BSO) REPORT:** The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the *NIH Guidelines*, (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.

   a. **Biosafety Officer Report**
      - Dr. Dhaka’s BUA *Transsynaptic Tracing of Somosensory Circuits* added human cells used in vitro in designated rooms.
      - Dr. Liu renewed the BUA *Quantitative molecular phenotyping to guide breast cancer lumpectomy*. This research uses human blood, tissue, body fluids, and cell lines in vitro.
      - Dr. Nilsson’s BUA *Microbial Lipid Extraction* added the use of non-recombinant microorganisms for in vitro work.
      - Dr. Gale’s BUA *The Host Response to Virus Infection* added cells infected with Zika virus and Sendai virus. It also added in vitro use of two Japanese encephalitis virus strains.
      - Dr. Mougous’ BUA *Type VI secretion-dependent interbacterial interactions* added the in vitro use of various non-recombinant Risk Group 2 organisms, as well as use of human blood and cells.
      - Dr. Wang renewed the BUA *Regulation of gene expression in cell proliferation and differentiation*. This BSL1 research uses Baculovirus, non-pathogenic E. coli strains, and recombinant or synthetic DNA/RNA (non-viral) enhanced gene delivery methods.
      - Dr. Savan’s Bua *Gene regulation of immune genes and the effect on immune responses* added the use of non-recombinant HSV-1, respiratory syncytial virus, and human rhinoviruses A, B, and C at BSL2.
      - Dr. O'Keefe’s BUA *Sample Processing for Clinical Research Studies* added a new laboratory space.
      - Dr. Jiang was approved for a new BUA, *Exploring the activity of zwitterionic polymer/peptide conjugated proteins*. This research uses human blood, tissue, body fluids, and cell lines.
      - Dr. Frevert’s BUA *Proteoglycans and Influenza Infection: Gene-targeted mouse models to study versican* added a new lab space for work with previously approved agents in mice.
      - Dr. Yu was approved for a new BUA, *In vitro study of mechanisms that contribute to ovarian cancer*. This research uses human blood, tissue, body fluids, and cell lines.
      - Dr. Shree is the new PI for the BUA *Shree Lab: Reproductive Sciences*, formerly under Dr. Gammill. This approval also reflects a move in lab location.
      - Dr. von Moltke’s BUA *Initiation of Type 2 Immune Responses* added use of Trichuris muris in mice. It also lowers containment of previously approved rodent helminths in Comparative Medicine vivariums.
      - The IBC Chair sought a motion to approve this month’s Biosafety Officer Report.
      - A member made a motion to approve this month’s Biosafety Officer Report. Another member seconded the motion.
      - The Committee unanimously voted to approve this month’s Biosafety Officer Report.

6. **DURC REPORT:**
• Dr. Gale’s project Host Response to BSL3 Pathogens received approval for continued use of Avian influenza virus. The lab uses homologous and heterologous strains of the H5N1 virus to challenge mice in evaluation of therapeutics and vaccines. The virus stocks are obtained from a collaborator and not propagated at the University of Washington.

• Dr. West’s project Host genetics and response to infection received approval for continued use of Burkholderia pseudomallei. The research is to understand how different elements of the host immune system regulate the response to infection with Burkholderia pseudomallei. The lab will culture and infect primary human cells with wild type or relevant mutant B. pseudomallei. The lab will assay a range of inflammatory responses and bacterial replication in the host cells. The lab will perform similar infections and assays in murine cells with specific genetic backgrounds, e.g. TLR5 knockout and wild type mice. They infect mice with wild type or mutant B. pseudomallei by several different routes and analyze the differences in bacterial replication, dissemination, and inflammatory responses in vivo. The group does not modify the pathogen.

• Dr. West’s project Drugamers to treat intracellular infection received approval for continued use of Burkholderia pseudomallei and Francisella tularensis. The lab evaluates whether candidate drugamers are effective in treating F. tularensis and B. pseudomallei respiratory infections in mice. The lab will infect mice via the respiratory route with wild type F. tularensis and B. pseudomallei. The drugamers are evaluated for therapeutic efficacy.

• All three projects were presented to the IBC by the DURC IRE Chair. A motion was made by the Chair to approve the DURC IRE’s recommendations. The motion was seconded. The committee voted unanimously to approve the recommendations of the DURC IRE.

7. PRESENTATION: BIOSAFETY LEVELS
   • A presentation was given to the Committee regarding biological safety level requirements and risk assessment processes.

8. SUBCOMMITTEE REPORT

a. Gottlieb, Geoffrey, appeal, Antiretroviral Therapy for HIV-2 Infection In Senegal
   • Four members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
   • Initial recommendation for plasmids containing full length HIV was for it to be performed at BSL2 containment. After discussion with the PI, subcommittee, and the NIH’s Office of Science Policy, the subcommittee recommends that all work with recombinant full length viral clones on plasmids capable of replicating in E. coli be handled at BSL1.
   • The draft BUA letter was shown. It states that recombinant III-E work will be performed at BSL1 and transfection into human cells will be performed at BSL2 with 3 practices.
   • A member made a motion to approve the Subcommittee’s recommendation.
   • The Committee voted unanimously to approve the Subcommittee’s recommendation and approve the draft BUA for Dr. Gottlieb. There was one abstention from a member who was not present at the April IBC meeting.

9. SECTION III-D AMENDMENTS

b. Buffalo, Elizabeth, renewal, Neurobiology of Memory
• The biosafety officer presented the BUA letter that was approved six months ago after a change to an IACUC protocol that involved biohazards. This BUA is being renewed in order to sync with IACUC approval.
• The lab was recently inspected, so a lab inspection was not required for this approval.
• All of the required trainings have been completed.
• The draft BUA letter was shown.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Buffalo.
• The Committee voted unanimously to approve the draft BUA for Dr. Buffalo.

10. INDIVIDUAL PROJECT REVIEWS

c. Bermingham-McDonogh, Olivia, renewal, Sensory cell development and regeneration in the inner ear
   • The assigned IBC Primary Reviewer presented the Primary Review.
   • This research aims to understand what signals are required to develop the sensory patches in the inner ear that are necessary for hearing and balance. Regeneration of hair cells after loss and how it affects the recovery of hearing and balance are being examined in transgenic mice.
   • The PI states that IDPN and tamoxifen are the greatest hazards being used.
   • The lab was inspected and no deficiencies were identified.
   • All of the required trainings have been completed.
   • The draft BUA letter was shown.
   • The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Bermingham-McDonogh.
   • The Committee voted unanimously to approve the draft BUA for Dr. Bermingham-McDonogh.

d. Cai, Shanshan, new, Innate immunity in pneumonic sepsis
   • The assigned IBC Primary Reviewer presented the Primary Review.
   • This project uses transgenic mice to study the role of innate immunity against RG2 bacteria infections in the lungs and extrapulmonary organs.
   • Noted biohazards include RG2 bacteria, human cell culture, 3rd generation lentiviral vectors, and siRNA delivery via lipofection.
   • Occupational health will be making recommendations for S. pneumonia.
   • The lab was inspected and no deficiencies were identified.
   • All of the required trainings have been completed.
   • The draft BUA letter was shown.
   • The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Cai.
   • The Committee voted unanimously to approve the draft BUA for Dr. Cai.

e. Chavkin, Charles, renewal, Chavkin: Mice
   • The assigned IBC Primary Reviewer presented the Primary Review.
   • This research aims to understand the effects of stress on motivated behavior, understand the molecular basis of addictive drug action, and develop novel strategies to treat drug addiction, mood disorders, and pain.
- Biohazards include work with adeno-associated viral vectors with reporter fusions to GFP that will be injected into mouse brains and used to transfect human, mouse, and rat cell lines. Gutless canine adenovirus vectors and CRISPR/Cas9 constructs will be used.
- This rare use of Myc is not a concern to the committee.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Chavkin pending a change to the BUA application.
- The Committee voted unanimously to approve the draft BUA for Dr. Chavkin pending a change to the BUA application.

f. Gale, Michael, change, *The Host Response to Virus Infection*
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - The lab is requesting to work with lentiviral vectors and recombinant RNA in vivo. These agents are currently approved for in vitro work on this BUA.
   - The lentiviral vectors cannot replicate, and only mouse cell lines will be used for in vivo experiments, eliminating the possibility of tumors forming in immune-competent human researchers if exposed.
   - The lab was recently inspected, and did not require an inspection for this change.
   - All of the required trainings have been completed.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Gale.
   - The Committee voted unanimously to approve the draft BUA for Dr. Gale.

g. Giachelli, Cecilia M., renewal, *Calcification and Cell Differentiation*
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - This project’s goal is to determine cell sources and molecular pathways involved in formation of vascular and valvular calcification in a variety of disease models, including atherosclerosis, chronic kidney disease, and diabetes mellitus.
   - The greatest biohazard risk to laboratory personnel is the work with amphotropic pseudotyped retroviral vectors and lentiviral vectors.
   - The lab was inspected and no deficiencies were identified.
   - All of the required trainings have been completed.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Giachelli.
   - The Committee voted unanimously to approve the draft BUA for Dr. Giachelli.

h. Golden, Sam, new, *PTSD-escalated aggression*
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - This project uses transgenic mouse models to identify the neural circuits underlying motivated behaviors and understand how these circuits are disrupted by neuropathological states caused by effects such as substance abuse and post-traumatic stress disorder. Biohazards include adeno-associated viral vectors expressing Cre-recombinase and containing cell-type-specific promoters.
   - The greatest biohazard listed is exposure to the mouse models.
   - The lab was inspected and no deficiencies were identified.
• All of the required trainings have been completed.
• The IACUC protocol listing these viral vectors has yet to be submitted.
• The draft BUA letter was shown.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Golden pending review of IACUC protocol.
• The Committee voted unanimously to approve the draft BUA for Dr. Golden pending review of the IACUC protocol once submitted.

i. Hernandez, Rafael E., renewal, Assessing bacterial and host contributions to Mycobacterium marinum pathogenesis in frogs and fish
   • The assigned IBC Primary Reviewer presented the Primary Review.
   • This lab seeks to understand the host-pathogen interactions that underlie pathogenesis of Mycobacterium tuberculosis and other mycobacterial diseases. Zebrafish are used as the infection model.
   • Transgenic work is done at Seattle Children’s Hospital. The agents will then be brought to UW for injection into zebrafish.
   • The IACUC protocol needs to remove use of S. aureus, which is not listed on the BUA renewal application, and is not included in the draft BUA letter.
   • The lab still needs to be inspected once the PI is set up.
   • All of the required trainings have been completed.
   • The draft BUA letter was shown.
   • The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Hernandez pending a successful lab inspection.
   • The Committee voted unanimously to approve the draft BUA for Dr. Hernandez pending a successful lab inspection and removal of an agent from their IACUC protocol.

j. Murphy, Sean, renewal, Immunity to malaria infection
   • The assigned IBC Primary Reviewer presented the Primary Review.
   • The goal of this research is to develop effective vaccines against malaria and other complex pathogens by studying infected mouse models and blood samples obtained from humans in malaria clinical trials.
   • The greatest biohazardous risks declared by the PI involve cultures of Listeria monocytogenes, P. falciparum, P. knowlesi and human PBMCs, and use of non-human primate cells.
   • The lab was inspected and no deficiencies were identified. Their space in HR&T cannot be inspected at this time due to closure, so it has been removed from this BUA application. It will be added later as a BUA change, and inspected at that time.
   • All of the required trainings have been completed.
   • The draft BUA letter was shown.
   • The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Murphy pending an addition to the BUA letter.
   • The Committee voted unanimously to approve the draft BUA for Dr. Murphy pending the addition to the BUA letter.

k. Murry, Charles E., renewal, Gene and Stem Cell Therapy in Swine
   • The assigned IBC Primary Reviewer presented the Primary Review.
• The goals of this research are to develop a new therapy for the treatment of heart failure and to develop a new therapy for the treatment of scar triggered arrhythmias in a swine model.
• The greatest biohazardous risk declared by the PI is the handling of highly concentrated adeno-associated viral vector stock.
• The lab was recently inspected for another BUA that was recently approved. An additional lab inspection was not required.
• All of the required trainings have been completed.
• The draft BUA letter was shown.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Murry pending a change to the BUA application.
• The Committee voted unanimously to approve the draft BUA for Dr. Murry pending a change to the BUA application.

I. Odom, Guy, new, Cardiopulmonary Gene Therapy for Muscular Dystrophy
• The assigned IBC Primary Reviewer presented the Primary Review.
• This research aims to address dystrophin replacement (structural-based therapy) to protect muscle cells from further injury while simultaneously improving cardiac muscle contractility and relaxation via a ribonucleotide reductase expression (contractile augmentation therapy).
• Adeno-associated viral vectors will be propagated in human cell lines, but these are not being grown in the PI’s laboratory.
• The lab was inspected and no deficiencies were identified.
• All of the required trainings have been completed.
• The draft BUA letter was shown.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Odom pending a change to the BUA application and one change to the BUA letter.
• The Committee voted unanimously to approve the draft BUA for Dr. Odom pending a change to the BUA application and one change to the BUA letter.

m. Park, James, renewal, Liver cancer theranostics
• The assigned IBC Primary Reviewer presented the Primary Review.
• This research evaluates the therapeutic efficacy and potential toxicity of beta- and alpha-particle emitting radioisotope-labeled targeted antibody treatment of a mouse model of human liver cancer.
• The greatest biohazard claimed by the PI is the use of human liver cancer cells that are injected into mice.
• The lab still needs to be inspected.
• All of the required trainings have been completed.
• The draft BUA letter was shown.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Park pending a successful lab inspection.
• The Committee voted unanimously to approve the draft BUA for Dr. Park pending a successful lab inspection.

n. Stetson, Daniel, change, Mechanisms and consequences of innate immune detection of nucleic acids
• The assigned IBC Primary Reviewer presented the Primary Review.
- The PI has requested to add vesicular stomatitis virus (VSV), Indiana strain, for in vivo and in vitro infections. Procedures include infection of human and mouse cells with VSV and intranasal infections of mice with VSV. Wild type and recombinant (expressing ovalbumin) VSV will be obtained from the Benaroya Research Institute for this research.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Stetson.
- The Committee voted unanimously to approve the draft BUA for Dr. Stetson.

o. Zweifel, Larry, renewal, Genetic Dissection of the Emotional Basis of Learning
- The assigned IBC Primary Reviewer presented the Primary Review.
- This lab studies the nature of how genes affect brain function and behavior in order to elucidate the basics of brain function during behavior, as well as how alterations in gene function can result in neurological and psychiatric disorders.
- Biohazards include in vitro and mouse work with adeno-associated viral vectors, in vitro and mouse work with canine adenoviral vectors, recombinant or synthetic DNA/RNA (non-viral) enhanced gene delivery methods, and human blood, tissue, body fluids, and cell lines.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Zweifel.
- The Committee voted unanimously to approve the draft BUA for Dr. Zweifel.

11. SUBCOMMITTEE REPORTS:

p. Trikudanathan, Subbulaxmi, new, Diabetes AutoimmunitY withdrawn in established patients (DAY)
- Two members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
- In this trial, a DNA plasmid encoding human pro insulin will be administered by IM injection in an attempt to modulate anti-insulin auto-immunity. Changing the character of the anti-insulin immune response is hoped to preserve and bolster the function of any residual, non-destroyed beta cells in the pancreas. This is in response to the chronic disorder T1D.
- The drug will be stored at UWMC pharmacy and distributed to the UW Roosevelt Clinic. After the first couple of weekly doses at the clinic, participants will pick up and self-administer the injections going forward.
- The patient is given a sharps container for use at home, which will then be disposed of as biohazardous waste.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Trikudanathan.
- The Committee voted unanimously to approve the draft BUA for Dr. Trikudanathan.
q. Trikudanathan, Subbulaxmi, new, Phase 3, DiabeteS AUtoimmNity WithdRawn In New OnSEt and In Established Patients (SUNRISE)
   - Two members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
   - In this trial, a DNA plasmid encoding human pro insulin will be administered by IM injection in an attempt to modulate anti-insulin auto-immunity. Changing the character of the anti-insulin immune response is hoped to preserve and bolster the function of any residual, non-destroyed beta cells in the pancreas. This is in response to the chronic disorder T1D.
   - The drug will be stored at UWMC pharmacy and distributed to the UW Roosevelt Clinic. After the first couple of weekly doses at the clinic, participants will pick up and self-administer the injections going forward.
   - The patient is given a sharps container for use at home, which will then be disposed of as biohazardous waste.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Trikudanathan.
   - The Committee voted unanimously to approve the draft BUA for Dr. Trikudanathan.

r. West, T. Eoin, renewal, Host genetics and response to infection
   - Four members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
   - This lab continues to work with Burkholderia pseudomallei and Francisella tularensis, both Select Agents and RG3 agents. The lab studies the interaction of these agents with human immune cells. They work with mouse models and precision-cut human lung slices.
   - Occupational Health recommendations are listed on the BUA letter. The Francisella vaccine is not required by Occupational Health.
   - The lab was inspected and no deficiencies were identified.
   - All of the required trainings have been completed.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. West
   - The Committee voted unanimously to approve the draft BUA for Dr. West.

s. BSL3 Inactivation
   - Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
   - The subcommittee proposed an inactivation policy requiring a demonstrated inactivation protocol from the PI. This involves validation and verification procedures. Personnel proficiency guidelines and considerations for specific protocols involving Hanta Virus and Tuberculosis were also reviewed by the subcommittee.
   - This document was sent to BSL3 users for feedback and their recommendations were reviewed and included.
   - Documenting training and competency is the lab’s responsibility.
   - A member made a motion to approve the Subcommittee’s recommendation.
   - The Committee voted unanimously to approve the Subcommittee’s recommendation pending the addition of training and competency requirements.
10. FOR YOUR INFORMATION:
   • Amendment to NIH Guidelines: A presentation was given to remind committee members of proposed 2018 changes to the NIH Guidelines regarding work with human gene transfer. The NIH has formally enacted these changes by amending the NIH Guidelines in April 2019.
   • CDC Polio Survey: The CDC has asked IBC Chairs to request that PIs complete the U.S. National Authority for Containment of Poliovirus survey. An email was sent to all PIs and lab managers.
   • NIH Incident Reports: An individual accidentally stuck their thumb with a needle that contained human 381T embryonal RMS cells harvested from immunodeficient mice. The individual was trying to homogenize the cells with a needle and syringe, which is not their standard operating procedure. The needle became clogged and trying to aspirate the cells, accidently poked their thumb. The individual followed post exposure procedures correctly and followed up with employee health for medical evaluation. This incident was reported to the NIH.

11. ISSUES FROM THE FLOOR & PUBLIC COMMENTS:
There were no issues from the floor, and no public comments.

12. MEETING ADJOURNED AT APPROXIMATELY 12:03 P.M.